Patentes

  1. Toledo J.R., Sánchez O., Rodríguez M.P. y Castro F.O., (2004). A method for the production of recombinant proteins in the mammary gland of non-transgenic mammals. PCT: WO 2004 /034780. [prioridad: 211002].

  2. Sánchez O., Toledo J.R., Díaz D., Figueroa N.E., Rodríguez M.P., Borroto C.G. Chimeric vaccine antigen against the avian influenza virus. PCT: WO2007/09878 A1. [prioridad 010206].

  3. Toledo J.R., Sánchez O., Barrera M., Figueroa N.E., Prieto Y., Rodríguez M.P., Frías M.T., Borroto C.G. Chimeric vaccine antigen against classical swine fever virus. PCT: WO2007/098717A2. [prioridad 010206].

  4. Toledo J.R., González I., Cerro R., Vera J., Zúñiga F., Lamperti L., Ormazabal V., Parra N., Sánchez O., Jiménez S., Oñate S., Rivas C. Moléculas inhibidoras del receptor LOX-1 y su incidencia directa en el control de la progresión tumoral en diversos tipos de cáncer humanos. Solicitud 2014-01709.

  5. Sánchez O., Toledo J.R., González I., Salgado E., Schulz D., Camacho F., Cabezas O., Huges F., González M., Salas A., Montesino R., Saavedra P. Método para la producción de proteínas recombinantes en glándula mamaria de mamíferos no transgénicos. Solicitud: 2014-02410.

  6. Sánchez O., Camacho F., Toledo J.R., Mansilla R., Zapata L., Salas A. Moléculas polipeptídicas contra el factor de crecimiento del endotelio vascular (VEGF). Solicitud: 2014-02941.

  7. Parra N., Sánchez O., Toledo J.R., Jiménez S., Camacho F., González I. Secuencia peptídica que reconoce y bloquea de forma específica al receptor de la lipoproteína de baja densidad oxidada (LOX-1). Solicitud: 2015-00616

 

Publicaciones

Publicaciones indexadas Revistas ISI:

  1. Adenoviral vector mediates high expression levels of human growth hormone in the milk of mice and goats. Sánchez O, Toledo JR, Rodríguez MP, Castro FO., J Biotechnol. 2004; 114 (1-2): 89-97.

  2. Differential in vitro and in vivo glycosylation of human erythropoietin expressed in adenovirally transduced mouse mammary epithelial cells. Toledo JR, Sánchez O, Montesino Seguí R, Fernández García Y, Rodríguez MP, Cremata JA., Biochim Biophys Acta. 2006; 1726 (1): 48-56.

  3. High expression level of recombinant human erythropoietin in the milk of non-transgenic goats. Toledo JR, Sánchez O, Seguí RM, García G, Montañez M, Zamora PA, Rodríguez MP, Cremata JA. J Biotechnol., 2006; 123 (2): 225-235.

  4. The goat mammary glandular epithelial (GMGE) cell line promotes polyfucosylation and N,N’-diacetyllactosediaminylation of N-glycans linked to recombinant human erythropoietin. Sánchez O, Montesino R, Toledo JR, Rodríguez E, Díaz D, Royle L, Rudd PM, Dwek RA, Gerwig GJ, Kamerling JP, Harvey DJ, Cremata JA. Arch Biochem Biophys., 2007; 464 (2): 322-334.

  5. Self-complementary sequences induce the formation of double stranded filamentous phages. Carratala Y, Sánchez O. Biochimica et Biophysica Acta., 2007; 1770 (8): 1081-1084.

  6. Monosialylated biantennary N-glycoforms containing GalNAc-GlcNAc antennae predominate when human EPO is expressed in goat milk. Montesino R, Toledo JR, Sánchez O, Sánchez A, Harvey DJ, Royle L, Dwek RA, Rudd PM, Gerwig GJ, Kamerling JP, Cremata JA. Arch Biochem Biophys., 2008; 470 (2): 163-175.

  7. Highly protective E2-CSFV vaccine candidate produced in the mammary gland of adenoviral transduced goats. Toledo JR, Sánchez O, Montesino R, Farnos O, Rodríguez MP, Alfonso P, Oramas N, Rodríguez E, Santana E, Vega E, Ganges L, Frias MT, Cremata J, Barrera M. J Biotechnol., 2008; 133 (3): 370-376.

  8. Classical swine fever virus E2 glycoprotein antigen produced in adenovirally transduced PK-15 cells confers complete protection in pigs upon viral challenge. Sánchez O, Barrera M, Rodríguez MP, Frías MT, Figueroa NE, Naranjo P, Montesino R, Farnos O, Castell S, Venereo A, Ganges L, Borroto C, Toledo JR. Vaccine, 2008; 26 (7): 988-997.

  9. Thermal stress treatment does not affect the stability and protective capacity of goat milk derived E2-marker vaccine formulation against CSFV. Barrera M, Sánchez O, Prieto Y, Castell S, Naranjo P, Rodriguez MP, Farnós O, Aguilera A, Frias M, Fonseca O, Figueredo JM, Aguero F, Montesino R, Toledo JR. Veterinary Immunology and Immunopathology, 2009; 127 (3-4): 325-331.

  10. N-Glycosylation Pattern of E2 Glycoprotein from Classical Swine Fever Virus. Montesino R, Toledo JR, Sánchez O, Zamora Y, Barrera M, Royle L, Rudd PM, Dwek RA, Harvey DJ, Cremata JA. J. Proteome Res., 2009; 8 (2): 546–555.

  11. Polyethylenimine-based transfection method as a simple and effective way to produce recombinant lentiviral vectors. Toledo JR, Prieto Y, Oramas N, Sánchez O. Appl Biochem Biotechnol., 2009; 157(3): 537-554.

  12. Nimotuzumab, an anti-tumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites S, Garrido G, Rabasa A, Lopez-Requena A, Pupo A, Johansen RF, Sánchez O, Krengel U, Moreno E. Cancer Research, 2009; 69 (14): 5851-5859.

  13. Early onset and long lasting protection in pigs provided by a classical swine fever E2-vaccine candidate produced in the milk of goats. Barrera M, Sánchez O, Farnós O, Rodríguez MP, Domínguez P, Tait H, Frías M, Ávila M, Toledo JR. Veterinary Immunology and Immunopathology, 2010; 133 (1): 25-32.

  14. All roads lead to milk: Transgenic and non-transgenic approaches for expression of recombinant proteins in the mammary gland. Castro FO, Toledo JR, Sánchez O, Rodriguez LL. Acta Scientiae Veterinariae. 2010; 38(Supl 2): s615-s626.

  15. Human αIFN co-formulated with milk derived E2-CSFV protein induce early full protection in vaccinated pigs. Toledo JR, Barrera M, Farnós O, Gómez S, Rodríguez MP, Aguero F, Ormazabal V, Parra NC, Suárez L, Sánchez O. Vaccine. 2010; 28(50):7907-7914.

  16. Avian CD154 enhances humoral and cellular immune responses induced by an adenovirus vector-based vaccine in chickens. Sánchez O, Gonzáles A, Gómez S, Parra NC, Amarán L, Noda J, Vega A, Díaz D, Águila JC, Toledo JR. Comp Immunol Microbiol Infect Dis., 2011, 34(3): 259-265.

  17. Dual promoter lentiviral vector generates transgenic mice expressing E2-CSFV glycoprotein in their milk, but impairs early identification of transgenic embryos. Sanchez O, Prieto Y, Gómez S, Parra NC, Suárez L, Jimenez SP, Toledo JR., Theriogenology, 2011, 75 (7): 1280–1289.

  18. First report of bovine herpesvirus 5 in bull semen. Rodríguez M, Barrera M, Sánchez O, Rodríguez EC, Martínez N, Parra NC, Toledo JR. Arch Virol., 2012; 157: 1775-1778. (Impact Factor: 2,39)

  19. Adenoviral vector-mediated expression of recombinant human glucocerebrosidase in the mammary gland of rats. Tavares KCS, Feltrin C, Carneiro IS, Morais AS, Medeiros CD, Castro FO, Toledo JR, Sanchez O, Renard G, Dias ACO, Chies JM, Santos DS, Bertolini M, Bertolini, LR. Reproduction, Fertility and Development, 2012, 25 (1): 314 – 315.

  20. Lectin-like oxidized LDL receptor-1 is an enhancer of tumor angiogenesis in human prostate cancer cells. González-Chavarría I, Cerro RP, Parra NP, Sandoval FA, Zuñiga FA, Omazábal VA, Lamperti LI, Jiménez SP, Fernandez EA, Gutiérrez NA, Rodriguez FS, Onate SA, Sánchez O, Vera JC, Toledo JR. PLoS One. 2014; 9(8):e106219.

  21. Effectiveness of the E2-CSFV recombinant vaccine produced and formulated within the whey of genetically transformed goats. Sánchez O, Barrera M, Farnós O, Parra NC, Salgado ER, Saavedra PA, Meza CD, Rivas CI, Cortez–San Martín M, Toledo JR. Clin Vaccine Immunol., 2014; 21(12): 1628-34.

  22. Secretion and assembly of calicivirus-like particles in high-cell-density yeast fermentations: strategies based on a recombinant non-specific BPTI-Kunitz-type protease inhibitor. Fernández E, Toledo JR, Mansur M, Sánchez O, Gil DF, González-González Y, Lamazares E, Fernández Y, Parra F, Farnós O. Appl Microbiol Biotechnol. 2015, 99(9): 3875-3886.

  23. Cis-regulatory elements involved in species-specific transcriptional regulation of the SVCT1 gene in rat and Human hepatoma cells. Muñoz A, Villagrán M, Guzmán P, Solíz C, Gatica M, Aylwin C, Sweet K, Maldonado M, Escobar E, Reyes AM, Toledo JR, Sánchez O, Oñate SA, Carlos Vera J, Rivas CI (2015) Free Radic. Biol. Med., 2015, 85:183-196.

  24. Post-translational modification of a chimeric EPO-Fc hormone is more important than its molecular size in defining its in vivo hematopoietic activity. Salgado ER, Montesino R, Jiménez SP, González M, Hugues F, Cabezas OI, Maura-Perez R, Saavedra P, Lamazares E, Salas-Burgos A, Vera JC, Sánchez O, Toledo JR. Biochim Biophys Acta. 2015, 1850(9):1685-1693.

  25. Expression and purification of the surface proteins from Andes Virus. Beltrán-Ortiz CE, Starck-Mendez MF, Fernández Y, Farnós O, González EE, Rivas CI, Camacho F, Zuñiga FA, Toledo JR, Sánchez O. Protein Expr Purif. Sep 12. pii: S1046-5928(15)30063-2. http://dx.doi.org/10.1016/j.pep.2015.09.013.

  26. Atomic Structure and Biochemical Characterization of an RNA Endonuclease in the N terminus of Andes Virus L Protein. Fernandez-Garcia Y, Reguera J, Busch C, Witte G, Sanchez-Ramos O, Betzel C, Cusack S, Guenther S, Reindl S. PLOS Pathogens. 2016; http://dx.doi.org/10.1371/journal.ppat.1005635.

Publicaciones indexadas Revistas SCIELO, LATINDEX, u otra.

  1. New procedure for the production of biopharmaceutical protein in the milk of non-transgenic animals. Toledo JR, Sánchez O, Montesino Seguí R, Fernández García Y, Cremata JA, Rodríguez MP Biotecnología Aplicada. 2005; 22 (1): 62-67.

  2. Molecular cloning and expression of a fragment of the gene codifying for the protein Erns of classical swine fever virus. Agüero JA, Sánchez O, Barrera M, Toledo JR. Rev. Salud Anim. 2008, 30 (2): 85-92.

  3. Knowing the glycosylation machinery of mammary gland cells: Potential and drawbacks for the expression of proteins of pharmaceutical interes. Cremata JA, Montesino R, Toledo JR, Sánchez O, Rodríguez EM, Rodríguez MP. Biotecnología Aplicada (2008) 25: 373-377.

  4. Desarrollo de controles positivos para métodos moleculares de detección de virus de influenza aviar. Acevedo AM, Santana E, Díaz de Arce H, Pérez LJ, Caballero A, Suárez L, Sánchez O. Rev. Salud Anim., 2009, 31(1): 1-5.

  5. Tecnología de presentación sobre fagos filamentosos en la búsqueda de agentes biológicos antiinfectivos. Vispo NS, Camacho F, Pupo M, Toledo JR, Sanchez O. Bionatura, 2015, 1(1):74-111.